Complete Clearance of Ph+ Metaphases after 3 Months Is a Very Early Indicator of Good Response to Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia

Publisher： Karger

E-ISSN： 1421-9662|129|2|126-134

ISSN： 0001-5792

Source： Acta Haematologica, Vol.129, Iss.2, 2012-11, pp. : 126-134

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Combination of EUTOS score and 3‐month BCR‐ABL transcript level identifies a group of good‐risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : E135-E137

John Wiley & Sons Inc

Access to resources Recommend Favorite

Promyelocytic Blast Crisis of Chronic Myelogenous Leukemia during Imatinib Treatment

By  

Acta Haematologica, Vol. 117, Iss. 4, 2007-02 ,pp. : 236-237

Karger

Access to resources Recommend Favorite

BCR-ABL1 Transcript Levels at 3 and 6 Months Are Better for Identifying Chronic Myeloid Leukemia Patients with Poor Outcome in Response to Second-Line Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure: A Report from a Single Institution

By  

Acta Haematologica, Vol. 134, Iss. 4, 2015-0 ,pp. : 248-254

Karger

Access to resources Recommend Favorite

Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib

By Goldberg Stuart L.   Chen Lei   Guerin Annie   Macalalad Alexander R.   Liu Nathan   Kaminsky Michael   Ericson Solveig G.   Wu Eric Q.  

Current Medical Research and Opinion, Vol. 29, Iss. 9, 2013-09 ,pp. : 1075-1082

Informa Healthcare

Access to resources Recommend Favorite

Chronic Myelogenous Leukemia with the e6a2 BCR-ABL and Lacking Imatinib Response: Presentation of Two Cases

By  

Acta Haematologica, Vol. 122, Iss. 1, 2009-07 ,pp. : 11-16

Karger

Access to resources Recommend Favorite